scispace - formally typeset
W

Wei Zheng

Researcher at Vanderbilt University

Publications -  23
Citations -  1882

Wei Zheng is an academic researcher from Vanderbilt University. The author has contributed to research in topics: Lymphangiogenesis & Vascular endothelial growth factor C. The author has an hindex of 14, co-authored 23 publications receiving 1603 citations. Previous affiliations of Wei Zheng include University of Helsinki & Helsinki University Central Hospital.

Papers
More filters
Journal ArticleDOI

Lymphangiogenic factors, mechanisms, and applications

TL;DR: Advances during the past decade have dramatically increased the knowledge of the mechanisms of lymphangiogenesis, including the roles of transcription factors,ymphangiogenic growth factors and their receptors, and intercellular and intracellular signaling cascades.
Journal ArticleDOI

A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11

Afshan Siddiq, +144 more
TL;DR: The largest meta-analysis of ER-negative disease to date, comprising 4754 ER- negative cases and 31 663 controls from three GWAS, identified two novel loci for breast cancer at 20q11 and 6q14 and confirmed three known loci associated with ER- Negative, triple negative and ER-positive breast cancer.
Journal ArticleDOI

VEGF-C is required for intestinal lymphatic vessel maintenance and lipid absorption

TL;DR: It is shown here that VEGF‐C is necessary for perinatal lymphangiogenesis, but required for adult lymphatic vessel maintenance only in the intestine, which could be especially important in the dietary regulation of adiposity and cholesterol metabolism.
Journal ArticleDOI

Effective Suppression of Vascular Network Formation by Combination of Antibodies Blocking VEGFR Ligand Binding and Receptor Dimerization

TL;DR: It is shown that combined use of antibodies blocking ligand binding and receptor dimerization improves VEGFR inhibition and results in stronger inhibition of endothelial sprouting and vascular network formation in vivo, suggesting that receptor Dimerization inhibitors could be used to enhance antiangiogenic activity of antibodiesblocking ligandbinding in tumor therapy.